A Comprehensive Corporate Summary — January 1, 2026 through August 31, 2026

Revenue record set three consecutive quarters: FY2025 $65.3M (+20%) → Q1 2026 $17.93M (+31%) → Q2 2026 $18.99M (+28.8%) → H1 2026 $36.91M (+29.7%). Annualized adjusted run-rate exceeds $75M. Full-year 2026 guidance: $90M+.
ATW $8M convertible note retired 12 months early: No further conversions, no dilution.
Strengthened balance sheet: H1 2026 total liabilities reduced 13.3% and stockholders’ equity increased 12.2%
Simplified capital structure: No shelf registration, no ATM, no floorless warrants.
5.1M+ shares repurchased for ~$1.11M under the $5M buyback.
Management increasing ownership: CEO Greg Siokas personally increased ownership by 3.3M+ shares in 2025 and a further 7.8M+ shares in 2026, bringing his total holding to 14.6M shares.
Zacks Small-Cap Research initiates coverage: $4.50 price target vs. a share price well below that level.
C-Scrub now in Tesco and Superdrug: placement in the UK's #1 and #2 health/beauty retailers, serving tens of millions of customers weekly; also establishing presence across hospital and surgical channels following EN 12791 certification, and entering the global animal health market.
Sky Premium Life global rollout: exclusive Saudi Arabia agreement with Innova Healthcare (126K units initial PO, 5M+ units projected over 5-year term), Qatar distribution agreement, third consecutive UAE order, and pan-European availability across all 27 EU Member States.
CCX0722 hydrogel patent (WO2025108566A1) filed in U.S., Europe, Australia and Canada — four markets inside a global weight-management category valued at $190.6B in 2025 and projected to reach $562B by 2033, growing at 14.2% CAGR.
18 Series U.S. buildout: Cur18™, Liv18™, Oliv18™ and Fort18™ launched/in production. NOOR Collagen DTC with >60% repeat rate. Combined projected U.S. revenue $22.7M+ at 70%+ gross margins.
$3.1M invested in digital asset portfolio in BTC + ETH. Bitcoin holdings now in a gain position.
~$20M in non-core assets identified for potential monetization — including wholly owned real estate and digital assets, without impacting core operations.
Operating cash requirements reduced by more than 30%, reflecting revenue growth, operating efficiencies and cost reduction initiatives
2029 guidance reaffirmed: $200.6M revenue — a 32% CAGR from FY2025 — alongside $71.2M gross profit, $31.0M net income and $44.2M Adj. EBITDA.

CHICAGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) today presents a comprehensive corporate update covering all significant operational, financial, and strategic milestones from January 1, 2026 through August 31, 2026.

The Company has executed across every dimension of its stated strategy in 2026: record revenue in every reporting period, a deleveraged and simplified balance sheet, a growing proprietary IP portfolio, meaningful U.S. brand launches, accelerating international expansion, AI-led operational upgrades, and active share repurchases. The update below is structured to give investors a complete view of that transformation.

COSM_KPI_Summary

I. Financial Performance: Three Consecutive Record Periods

Cosmos Health has delivered its highest revenue in Company history across every reporting period in 2026, building on a record FY2025:

FY2025: Revenue $65.27M (+20% YoY) — the strongest annual result in Company history. Gross profit surged 83% to $7.9M. Gross margin expanded 418 basis points. Adjusted EPS improved 82%. Cash rose more than tenfold to $3.5M. Every core segment contributed: CosmoFarm expanded its pharmacy network, Cana scaled contract manufacturing under long-term agreements, Decahedron grew UK distribution, and Sky Premium Life expanded globally.

Q1 2026: Revenue $17.93M (+30.7%) — record Q1. Total liabilities declined $4.5M (-9.6%). Stockholders’ equity +7.6%. Liabilities-to-assets ratio improved to 68.2% from 71.9% at year-end 2025. Adjusted EBITDA near breakeven. Broad-based commercial strength: 75+ pharmacies added at CosmoFarm, Sky Premium Life growth across multiple markets, expanded Cana orderbook.

Q2 2026: Revenue $18.99M (+28.8%) — record Q2. H1 2026 $36.91M (+29.7%). Adjusted gross profit +58% YoY. Total liabilities −$6.27M (−13.3%). Stockholders’ equity +12.2%. Liabilities-to-assets ratio improved 550 basis points. Annualized adjusted run-rate exceeded $75M. Every core division contributed: CosmoFarm 75+ pharmacies, Cana orderbook 25M+ units all-time high, Decahedron near-doubled UK revenue.

Operating Efficiency: operating cash requirements in H1 2026 ran more than 30% below the average of the prior two years, reflecting revenue growth, operating efficiencies and disciplined cost control — a meaningful step toward the Company’s 2027 profitability targets.

METRIC	FY2025	Q1 2026	Q2 2026	H1 2026
Revenue	$65.27M (+20%)	$17.93M (+31%)	$18.99M (+28.8%)	$36.91M (+29.7%)
Adj. Gross Profit	$7.9M (+83%)	$1.85M	+58% YoY	Expanding
Total Liabilities	Improved	−$4.5M (−9.6%)	−$6.27M (−13.3%)	550bps improvement
Stockholders’ Equity	Improved	+7.6%	+12.2%	Consistent growth
Adj. EBITDA	Improving	−$229K (near breakeven)	−$1.13M (improved)	Trend up

II. Strengthened Balance Sheet and Capital Structure

The most consequential financial development of 2026 is the transformation of Cosmos Health’s capital structure. The Company has methodically removed meaningful dilution overhang mechanisms and, as a result, expects its share count to remain broadly stable under its existing capital structure, before accounting for the reduction from ongoing share repurchases.

Convertible note repaid: On August 28, 2026 the Company repaid in full its $8.0 million senior secured convertible note issued to ATW in August 2025, together with all accrued interest, twelve months ahead of its August 2027 maturity. The repayment eliminates any further conversions or dilution from that instrument.
Shelf registration withdrawn: The Company has withdrawn its Form S-1 and Form S-3 registration statements. No effective shelf registration or ATM offering program is in place.
No structured or floorless warrants: Remaining warrants carry fixed exercise prices with no reset or ratchet provisions. In May 2026, 4,874,126 Series B warrants expired unexercised with no new shares issued, removing approximately 38% of the total warrant overhang. The next tranche of warrants carries an exercise price of $0.95 per share, significantly above the current share price.
Share repurchase program: 5,112,000 shares have been repurchased for approximately $1.11 million under the $5.0 million authorization, with open market purchases ongoing.
Non-core assets: ~$20M in non-core assets identified for potential monetization (real estate, digital assets, marketable securities), including $15M in real estate at fair market value and $3.1M invested in digital assets (BTC + ETH). Bitcoin holdings are currently in a gain position.

	DECEMBER 31, 2025	JUNE 30, 2026	CHANGE
Total liabilities	$47.05M	$40.79M	−$6.27M / −13.3%
Stockholders’ equity	$18.42M	$20.67M	+$2.25M / +12.2%
Liabilities-to-assets ratio	71.9%	66.4%	550 basis points improvement

III. Diversified Asset Base and Digital Assets Strategy

The Company maintains a diversified asset base spanning liquid assets, digital holdings and real estate, alongside access to non-dilutive financing. Together these provide flexibility to fund the Company’s next phase of growth without recourse to equity issuance. As previously stated, the Company has identified approximately $20 million in non-core assets for potential monetization that can be converted to liquidity without impacting core operations. These primarily comprise digital assets, in which over $3 million has been invested to date, and a real estate portfolio with a fair market value of approximately $15 million.

Digital Assets

Cosmos Health has built a disciplined digital asset program as a component of its treasury strategy, with initial focus on Ethereum and strategic expansion into Bitcoin:

February 2026: $500K Bitcoin purchase — total investments in digital holdings reach $2.5M
March 2026: $600K Bitcoin purchase — total investments in digital holdings reach $3.1M
August 2026: Bitcoin holdings in a gain position as of the date of this release, available for opportunistic monetization

Real Estate

Beyond its liquid and digital assets, Cosmos Health owns a valuable real estate portfolio, with an independent fair market valuation placing it at approximately $15 million. The portfolio comprises the Cana Laboratories’ manufacturing facility in Athens, on a land plot of approximately 54,000 square feet, and the CosmoFarm logistics center in western Athens, of approximately 29,100 square feet. Both properties are wholly owned by the Company. Management regards this as a further resource available to the Company.

European Investment Bank financing

In May 2026, Cana Laboratories entered into an advisory agreement with the European Investment Bank (EIB) for the financing of a €50 million R&D program, under which EIB financing could represent up to 50%, or €25 million, under the EIB’s Venture Debt Program. This sits alongside available credit facilities and other non-dilutive financing sources that may be explored.

IV. Analyst Coverage and Valuation

On January 14, 2026, Zacks Small-Cap Research initiated analyst coverage of Cosmos Health with a $4.50 price target — representing a significant premium to where the stock has traded. The initiation cited the Company’s revenue trajectory, brand portfolio and proprietary pipeline as key drivers. Analyst estimates and price targets represent the views of the issuing firm and not those of the Company.

V. Divisional Performance Snapshot

DIVISION	2026 KPI	KEY MILESTONES
CosmoFarm	>$15M / Q2	Record Q2; $60M+ annualized run-rate. 80+ pharmacies added. AI robotic automation & inventory management deployed. LOI signed to acquire $11.5M pharmacy distribution network.
Cana Laboratories	25M+ unit orderbook	All-time high contract manufacturing backlog; multi-year agreements up to 10 years. >$10M projected recurring annual profit. Verisfield: 3.9M-unit agreement. Pharmex: 2.86M-unit agreement (3 dermatological products). Provident: 385K units with new capsule production line inaugurated. Nassington and Verisfield: 253,657 additional units. EU GMP-certified.
Decahedron (UK)	Near 2× revenue	Nearly doubled revenue YoY in Q2 2026. Key distribution hub for UK/European markets with continued growth momentum.
18 Series / NOOR	$22.7M+ proj.	Cur18™, Liv18™, Oliv18™ and Fort18™ launched or in production. NOOR Collagen >60% repeat rate, >50% margins. U.S. subscription model live; broader digital platform in development. DTC e-commerce + planned retail expansion.
Sky Premium Life	5M+ units / Saudi	Saudi Arabia: exclusive 5-year deal with Innova Healthcare (126K initial PO, 5M+ units projected). Qatar: agreement with International Medical Company (31K initial order). UAE: third consecutive Pharmalink order (60K units, 270K cumulative). EU: all 27 Member States via Skroutz. Albania (54K+ annual units), UK and expanding.
C-Scrub / C-Sept	UK + hospital + animal health	C-Scrub live at Tesco (#1 UK retailer, ~30% market share) AND Superdrug (#2 health & beauty, 830+ stores). EN 12791 certification for surgical hand disinfection. C-Sept PRO gaining traction in Greek hospital groups (~72% gross margin). Veterinary C-Scrub launched into $69B animal health market (EN 1656/1657 certified).
CCX0722 Hydrogel	4 patent markets	WO2025108566A1 advanced into US, EU, Australia & Canada. Mechanical satiety platform — swells more than 100-fold in the stomach with no systemic absorption. Market: $190.6B (2025) → $562B by 2033. Owned outright by Cana. No royalties, no third-party IP dependency.

VI. UK Retail Breakthrough, New Channels and Growth Initiatives

In February 2026, Cosmos Health achieved a landmark dual placement for C-Scrub in the United Kingdom — securing listings with two of the largest retailers in the country:

Tesco: The UK’s largest retailer, holding ~30% market share and generating over $80B in annual revenue globally. Tens of millions of customers served weekly.
Superdrug: The UK’s second-largest beauty and health retailer, operating 830+ stores including 200+ in-store pharmacies across the UK and Republic of Ireland, plus a strong e-commerce platform.

The listing in both retailers represents a step-change in C-Scrub’s UK visibility and credibility, and establishes a platform for potential rollout of additional Cosmos Health products. The Company has since extended the franchise into two additional channels:

Hospital and surgical (April 2026): C-Scrub Wash 4% completed testing under EN 12791, the European standard for surgical hand disinfection, supporting entry into hospital, surgical and professional healthcare procurement channels. C-Sept PRO has since gained traction across leading Greek public and private hospital groups.
EU expansion: C-Scrub and C-Sept reported annualized sales above $1.5 million at gross margins over 70%, with planned European expansion targeting $2.5 million in revenue in 2026, rising to $7.4 million in revenue and $5.3 million in gross profit by 2028.
Animal health (June 2026): Veterinary C-Scrub Wash 4% certified under EN 1656 and EN 1657 European standards — opening the $69B global animal health market. The veterinary line extends an existing certified formulation manufactured in-house at Cana’s facility.

Acquisitions

The Company is actively exploring acquisitions that could be immediately accretive and accelerate progress toward its stated guidance targets. Two letters of intent (LOI) have been signed to date:

Pharmacy distribution network (March 2026): LOI signed to acquire a $11.5M pharmacy distribution network, further expanding CosmoFarm’s reach.
Doc Pharma S.A. (June 2026): LOI signed to acquire Doc Pharma S.A., an affiliated European GMP pharmaceutical manufacturer, expected to expand assets, production capacity, product portfolio and profitability.

VII. International Expansion: Saudi Arabia, Dubai, and Global Markets

Cosmos Health accelerated the international rollout of its proprietary brands during 2026, adding exclusive and long-term distribution partnerships across the Gulf while achieving full European coverage for Sky Premium Life. Each agreement is with an established distributor holding significant retail reach in its market.

Saudi Arabia (August 2026): Cosmos Health entered the Kingdom of Saudi Arabia through an exclusive five-year distribution agreement with Innova Healthcare, one of the Kingdom’s largest retail pharmacy networks, operating more than 250 pharmacies with a stated plan to exceed 500. The agreement covers the full Sky Premium Life range. An initial purchase order of 126,000 units was secured on execution, with total expected volume exceeding 5 million units over the initial five-year term. Innova holds a first right of refusal on new Cosmos Health products developed or acquired during the term.

Qatar (June 2026): The Company signed a distribution agreement with International Medical Company, whose Kulud Pharmacies retail arm is the country’s largest chain with more than 130 branches, securing an initial order of 31,000 Sky Premium Life units.

United Arab Emirates (April 2026): A third consecutive purchase order was received from Pharmalink for 60,000 Sky Premium Life units, taking cumulative orders to 270,000 units against a five-year goal of over 3 million units.

European Union (June 2026): Pan-European distribution was achieved for Sky Premium Life through the e-commerce platform Skroutz, making 96 products available for shipment across all 27 EU Member States.

Albania (July 2026): Pharma Cell partnership scaled to 4,500+ monthly units, with annualized orders projected to exceed 54,000 units. Products are distributed across Albania and recommended by healthcare professionals.

Dubai (February 2026): Cosmos Health showcased its expanding brand portfolio at the World Health Expo Dubai 2026, reinforcing the Company’s presence in the Middle East and MENA region.

VIII. CCX0722 Hydrogel: International Patent in Four Markets

On June 25, 2026, Cana Laboratories advanced international patent application WO2025108566A1, "Hydrogel for Body Weight Management," into the European regional phase and national phases in the United States, Australia and Canada. The IP was acquired outright from Cloudpharm on June 8, 2026 — no licensing fees, no royalty-sharing, no third-party dependency.

CCX0722 works through a simple, mechanical mechanism with no systemic absorption. Taken as a capsule before meals, the dried hydrogel absorbs water in the stomach and swells more than 100-fold into soft gel pieces that occupy stomach volume to support satiety, before naturally passing through the GI tract. The global weight management market was $190.6B in 2025 and is projected to reach $562.2B by 2033 at a 14.2% CAGR.

IX. U.S. Proprietary Brand Buildout: The 18 Series Platform

The 18 Series is Cosmos Health’s portfolio of science-validated nutraceutical products, manufactured in the United States at facilities holding GMP certification and FDA registration. The following products are now in active U.S. commercial launch or production:

Cur18™ — Patented, clinically studied curcumin formulation delivering up to 39× higher free curcumin bioavailability versus standard 95% curcuminoid extracts. U.S. commercial launch Q2 2026.
Liv18™ — Clinically validated liver health supplement. Phase 1 complete; production commenced April 2026 at a GMP-certified, FDA-registered, UL-audited U.S. facility. Projected $5M+ annual revenue at ~75% gross margin. Tariff-mitigated via U.S.-based manufacturing.
Oliv18™ — Whole olive polyphenol; USDA and EU organic certified; 100% solvent-free. Targeting U.S. cardiovascular and antioxidant categories. Projected $6M+ annual revenue at ~72% gross margin within 12–18 months.
Fort18™ — Men’s wellness supplement introduced May 2026. Projected $3.2M+ incremental annual U.S. revenue within 12–18 months.
NOOR Collagen — Korean-developed premium collagen. Subscription model launched with >60% early repeat purchase rate at >50% gross margins. Projected $12M+ annualized revenue. Entering $163B global skincare market.

Combined, the 18 Series / NOOR U.S. portfolio projects over $22.7M in annualized revenue at approximately $17.0M in gross profit — structurally high-margin, DTC-led, and subscription-capable.

X. AI Strategy and Operational Infrastructure

AI has moved from strategy to execution at Cosmos Health in 2026, with deployments across commercial, logistics and research functions:

Enterprise integration (April 2026): AI deployed across front-end order and customer management, back-end warehouse, inventory and supply chain operations, and the proprietary Cloudscreen drug repurposing platform — with the potential to reduce certain operating expenses by up to 30%.
CosmoFarm automation: AI robotic automation deployed for inventory management and order fulfillment, alongside expanded facility capacity supporting an additional $40M+ in annual revenue capacity.
Customer operations (June 2026): AI-powered call center agreement signed — multilingual voice, outbound campaigns and real-time reporting — to optimize order intake and customer communications.
Subscription platform (July 2026): The Company is actively developing an AI-enabled digital subscription platform spanning consumer (B2C) and corporate (B2B) channels, building on the U.S. subscription launch of NOOR Collagen, which has delivered an early repeat purchase rate above 60%.

These investments underpin the operating leverage the Company expects to demonstrate as revenue scales toward $90M and beyond.

XI. 2026–2029 Financial Guidance Reaffirmed

The Company reaffirms its guidance issued May 26, 2026. H1 2026 performance is consistent with the trajectory required to achieve these targets:

METRIC	FY2025 (actual)	2026 (guidance)	2027 (guidance)	2029 (guidance)
Revenue	$65.3M	>$90M (+38%)	$130.7M	$200.6M
Gross Profit	$7.9M (12.1%)	Expanding	$36.7M	$71.2M (35.5%)
Net Income	Loss	Near B/E path	$8.7M	$31.0M
Adj. EBITDA	Improving	Improving	$16.5M	$44.2M
Cash	$3.5M	Stable+	$17.3M	$62.9M

The 32% CAGR is expected to be driven by a structural margin shift toward proprietary segments: the 18 Series (72–75% gross margins), CCX0722 licensing/co-development, and Cana contract manufacturing — alongside continued organic growth in distribution.

Management believes that achieving these targets would create significant value for shareholders, as the Company transitions to a self-funded model driven by strong cash flows.

XII. Complete 2026 Milestone Timeline

DATE	MILESTONE
Jan 14	Zacks Small-Cap Research initiates analyst coverage with $4.50 price target
Jan 20	Accelerating CosmoFarm customer growth; robotic expansion supporting $40M+ additional annual revenue
Feb 11	$500K Bitcoin purchase — digital asset program expanded to $2.5M total
Feb 17	Cosmos Health showcases expanding brand portfolio at World Health Expo Dubai 2026
Feb 18	C-Scrub listed at Tesco, the UK’s largest retailer (~30% market share)
Feb 18	C-Scrub listed at Superdrug, the UK’s 2nd-largest beauty & health retailer (830+ stores)
Feb 19	Company highlights $15M fair market value of real estate assets
Mar 10	$600K Bitcoin purchase — total digital asset holdings reach $3.1M
Mar 11	LOI signed to acquire $11.5M pharmacy distribution network
Mar 19	Corporate update: NOOR Collagen projected at $12M+ annualized
Apr 1	C-Scrub Wash 4% completes EN 12791 testing for surgical hand disinfection
Apr 8	Planned U.S. launch of Liv18™ announced
Apr 13	Third consecutive Pharmalink purchase order — 60,000 Sky Premium Life units for the UAE
Apr 15	FY2025 results: Record $65.27M revenue (+20%), gross profit +83%, gross margin +418bps, cash 10× to $3.5M
Apr 16	Enterprise AI integration announced — potential to reduce certain operating expenses by up to 30%
Apr 17	Cur18™ U.S. commercial launch announced for Q2 2026
Apr 20	Liv18™ Phase 1 complete; production commencing at GMP/FDA-registered U.S. facility — $5M+ projected at ~75% gross margin
Apr 30	Cur18™ projected to contribute $2.5M+ in incremental annual U.S. revenue
May 6	Fort18™ introduced, extending the 18 Series into men’s wellness
May 11	Fort18™ projected to contribute $3.2M+ in incremental annual U.S. revenue
May 12	Registration Statement on Form S-1 withdrawn
May 14	Advisory agreement signed with the European Investment Bank for a €50M R&D program (up to €25M)
May 21	Q1 2026 results: Record $17.93M (+31%); liabilities −$4.5M; equity +7.6%; Adj. EBITDA near breakeven
May 21	4,874,126 Series B warrants expire unexercised — 38% of warrant overhang removed with no dilution
May 26	2026–2029 financial guidance: $90M in 2026, $200.6M by 2029 at 32% CAGR
Jun 1	Veterinary C-Scrub Wash 4% launched — entry into the $69B global animal health market
Jun 4	Pan-European distribution achieved for Sky Premium Life across all 27 EU Member States via Skroutz
Jun 4	$20M non-core assets identified for potential monetization (real estate, digital assets, securities)
Jun 5	Oliv18™ launched in the United States
Jun 8	Cana Laboratories acquires CCX0722 patent application from Cloudpharm — full IP ownership consolidated
Jun 9	New capsule production line inaugurated; five-year Provident agreement for 385,000 units of CERTORUN
Jun 10	Three-year, 3.9M-unit contract manufacturing agreement signed with Verisfield
Jun 11	LOI signed to acquire Doc Pharma S.A., an affiliated European GMP pharmaceutical manufacturer
Jun 12	C-Scrub and C-Sept annualized sales exceed $1.5M at 70%+ gross margins; EU expansion targeting $7.4M revenue by 2028
Jun 12	Contract manufacturing orders totaling 253,657 units received from Nassington and Verisfield
Jun 15	U.S. portfolio update: four 18 Series products with $22.7M+ projected annualized revenue at ~$17M gross profit
Jun 17	Pharmex S.A. contract manufacturing agreement: 2.86M units across three dermatological products
Jun 17	Entry into the $163B global skincare market — Korean collagen brand already live in the U.S.
Jun 18	CosmoFarm delivers record Q2 >$15M revenue; $60M+ annualized run-rate; 80+ pharmacies added
Jun 22	Cana orderbook hits all-time high of 25M+ units; >$10M recurring annual profit projected
Jun 23	AI-powered call center agreement signed for CosmoFarm customer communications
Jun 24	C-Sept PRO gains traction across Greek hospital groups — $1.3M+ annualized at ~72% gross margin
Jun 25	International patent application WO2025108566A1 advanced into US, EU, Australia and Canada
Jun 26	Distribution agreement signed with International Medical Company for Qatar — 31,000-unit initial order
Jun 30	Board authorizes $5.0M share repurchase program
Jul 7	Preliminary Q2 record revenue ~$19.4M; 3.64M shares repurchased under $5M buyback
Jul 10	Subscription model launched with NOOR Collagen — >60% repeat purchase rate, >50% gross margins
Jul 13	Agreement signed with Libytec to commercialize DIABIT-IS X in Greece
Jul 17	Buyback reaches 5.11M shares repurchased for ~$1.11M; open market purchases ongoing
Jul 20	Albania expansion: Pharma Cell partnership scaled to 4,500+ monthly units, 54K+ annually
Jul 27	AI-enabled digital subscription platform announced across B2C and B2B channels
Aug 19	Q2 2026 results confirmed: $18.99M (+28.8%); H1 $36.91M (+29.7%); adj. gross profit +58%
Aug 20	Saudi Arabia entry: exclusive 5-year deal with Innova Healthcare; 126K initial PO; 5M+ units projected
Aug 24	Oliv18™ projected to generate $6M+ annual U.S. revenue at ~72% gross margin within 12–18 months
Aug 28	$8M ATW convertible note retired 12 months ahead of maturity; no further dilution

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated: "This is a different company than it was twelve months ago. We have retired $8 million of debt a full year early. We repurchased more than five million shares. We delivered record revenue in every reporting period. We placed C-Scrub in Tesco and Superdrug. We entered Saudi Arabia with a five-year exclusive distribution agreement. We filed our hydrogel patent across four global markets. We launched proprietary U.S. brands. And we did all of this while cutting our cash burn by more than 30%.

"Every pillar of our strategy is delivering. CosmoFarm is growing its pharmacy network and deploying AI. Cana has its biggest contract manufacturing orderbook in history. Decahedron nearly doubled its UK revenue. Our proprietary brands are gaining real commercial traction.

"We enter the second half of 2026 with a solid balance sheet and a streamlined capital structure, growing revenue across every division, and a clear path to $200 million in revenue and significant profitability by 2029. Cosmos is not a promise. It is performance."

About Cosmos Health Inc.

Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.

Investor Relations Contact:

BDG Communications

cosm@bdgcommunications.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b3c3061f-2b75-4eaf-9ca4-2e98bdd664b2